contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


rene-eve-appointed-as-director-of-operations-of-bioretec-ltd

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Here are Mr. Siltanen’s comments on how Bioretec’s change negotiations have been concluded.  Bioretec announced on Thursday that it had concluded the change negotiations initiated in November. As a result of the negotiations, the company will lay off two employees and furlough five production employees. The targeted savings are moderate in size, and they do not change the company’s big picture. The announcement does not cause immediate changes to our forecasts.                   Inderes              Bioretecin muutosneuvottelut päätökseen - Inderes    Bioretec tiedotti torstaina saaneensa päätökseen marraskuussa aloitetut muutosneuvottelut.

Certainly, if relevant information has been provided, we must now patiently await new steps!

It would be nice to hear an update from the company so that we don’t completely lose hope. One could assume that the restructuring also includes a very intensive search for channels through which sales could pick up. The stock price is at least quite low, but I already bought some more when it felt good. I didn’t buy quite this low, though. It’s affordable to get involved now if you don’t own any yet or to add to your holdings. I personally find it more likely that the wait will eventually pay off than that such a complete and good product would ultimately flop.

If Alan Donze slipped into hiding, it could also be because he simply realized he had messed everything up, burned out… such cases have been seen… It’s just a shame that it fell on Bioretec’s shoulders.

Here is a new company report on Bioretec from Antti.  Bioretec’s Q3 business review shed light on the company’s situation and the commercial challenges of the RemeOs product family. Growth for the new product family is expected to be delayed until 2026. The company is seeking new commercial momentum through recruitments, changes in its distribution model, and a strategy update at the end of the year. In addition to business improvements, investor confidence, which has taken a hit, needs to be rebuilt over time. We are revising our forecasts downwards due to the weak outlook, based on which we lower our target price to 1.05 euros (previously 1.2 euros) and reiterate our add recommendation. The risk of capital loss in the investment remains high, which is balanced by a rather low absolute valuation.                   Inderes              Bioretec: Uuden alun rakentamista - Inderes    Bioretecin Q3-liiketoimintakatsaus valotti yhtiön tilannetta ja RemeOs-tuoteperheen kaupallisia haasteita.

And here’s a link to the interview where Antti interviewed CEO Sarah Hubar-Fisher regarding Q3.                   Inderes              Bioretec Q3'25: Necessary revisions ahead - Inderes    Aika: 13.11.2025 klo 11.55 In connection with its Q3 business review, Bioretec shed light on its situation and the commercial challenges of the RemeOs product family. The company is seeking new commercial momentum through recruitment and revisions to...                             Topics: 00:00 Introduction  00:12 H1 figures revisions  01:20 Summary of the third quarter  02:34 Gross profit  03:51 Status of the RemeOs launch in Europe  04:48 Reasons for the distribution model revision  07:23 Increased headcount  09:05 Change negotiations  10:30 Targets and strategy update  11:39 Timeline for clinical trial  12:32 Screw model approvals and indication expansions in the US  13:23 Cash runway  14:08 Turning the cash flow positive  14:45 Outlook for the rest of the year and 2026

Good day! So… is the CEO’s interview coming today @Antti_Siltanen? …and there the interview already came… thanks.!

Bioretec

Bioretec Ltd Press release 11. July 2025 at 8.00 amBioretec has appointed Bachelor of Technology René Eve as the company's Director of Operations and as a member of the Management Team. Eve ...

<div class="abstract">Bioretec Ltd&nbsp;&nbsp;&nbsp;Press release&nbsp;&nbsp;&nbsp;11. July 2025 at 8.00 am</div>Bioretec has appointed Bachelor of Technology René Eve as the company's Director of Operations and as a member of the Management Team. Eve has over 15 years of diverse experience in production, procurement, production planning, and customer service. René Eve joins Bioretec from Next Pharma and takes up his duties on 18 August 2025. Esa Hallinen, former Director of Operations, will pursue a career outside Bioretec. &nbsp;"Bioretec is significantly expanding its operations and production after obtaining both U.S. FDA approval and CE Mark approval for the RemeOs™ product family of absorbable orthopedic implants in Europe and all other countries where CE Mark is recognized. René Eve has strong expertise in the pharmaceutical industry and mass manufacturing of metal products.&nbsp;He will play a key role in Bioretec's growth into the next phase of commercialisation for our RemeOs and Activa™ products globally. We are excited to welcome René Eve to our experienced management team," Bioretec's interim CEO Sarah van Hellenberg Hubar-Fisher says.&nbsp;"It's great to join Bioretec's innovative team and support the company's growth and international success story. I am looking forward to implementing the company's strategy and bringing the production of absorbable implants to the next level," René Eve says. <div></div>